Previous 10 | Next 10 |
home / stock / acogf / acogf news
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,...
The following slide deck was published by Alpha Cognition Inc. in conjunction with this event. For further details see: Alpha Cognition (ACOGF) Investor Presentation - Slideshow
Virtual Conference for Life Sciences Companies Broadcast Live December 16th Canada NewsWire Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , Dec. 14, 2021 /CNW/ - Virtual Investor Co...
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th Company executives will share corporate vision and answer audience questions at VirtualInvestorConferences.com PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Vi...
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,...
LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Canada Vir...
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today...
Alpha Cognition (OTC:ACOGF): Q3 GAAP EPS of -C$0.09. Cash and cash equivalents were C$5.6M vs. C$5.6M Q2-2020. Press Release For further details see: Alpha Cognition reports Q3 results
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB:ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, ...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
News, Short Squeeze, Breakout and More Instantly...
The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Pro...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...